RT Journal Article
SR Electronic
T1 Residential Methamphetamine Contamination in Boulder Colorado: Incidence and Implications
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.28.24311138
DO 10.1101/2024.07.28.24311138
A1 Dennison, James E.
A1 Minick, Norris
YR 2024
UL http://medrxiv.org/content/early/2024/07/30/2024.07.28.24311138.abstract
AB The manufacture and use of methamphetamine (meth) is a significant problem, in part because it can lead to the contamination of properties where it occurs. Meth contamination can lead to health issues for occupants as well as very high remediation costs for property owners. But even in a state like Colorado, where meth testing and remediation are highly regulated, the number of residences or other types of property that are contaminated in excess of health standards is unknown. Generally, testing for meth contamination occurs only after a property is identified as a likely site for meth use or manufacture, whether by law enforcement, the property owner, or a potential buyer. For this paper, a unique random data set based on a real estate broker’s meth screening program was used to determine the incidence of contaminated residences in general. Brokerage clients put 303 residential properties under contract between 2013 and 2022, of which 288 (95%) were screened for meth contamination. Meth was detected in 45 of the 288 screening tests (16%), many at trace levels, while 84% contained no detectable meth. Comprehensive testing was subsequently performed on 35 of these 45 properties and ten of the original 288 (3.47%) screened properties contained meth contamination above state health standards. While the sample size of this analysis was modest, it provides a first real estimate of the incidence of meth-contaminated residential property and an indication of the environmental health significance of this issue.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors